Category: Editas

Editas Medicine (NASDAQ:) has reported significant strides in its first quarter of 2024, focusing on delivering innovative treatments for genetic diseases. The company emphasized its strategy, which includes advancing its gene editing therapy reni-cel towards commercialization, developing an in vivo editing pipeline, and enhancing business development to monetize intellectual property.…